Nicholas Investment Partners, LP Supernus Pharmaceuticals, Inc. Transaction History

Nicholas Investment Partners, LP

  • $845 Million
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018
SELL
$42.7 - $56.55 $3.3 Million - $4.37 Million
-77,214 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$44.1 - $59.85 $21,300 - $28,907
483 Added 0.63%
77,214 $4.62 Million
Q1 2018

May 15, 2018
BUY
$37.15 - $46.9 $60,740 - $76,681
1,635 Added 2.18%
76,731 $3.51 Million
Q4 2017

Feb 14, 2018
BUY
$36.4 - $42.6 $44,662 - $52,270
1,227 Added 1.66%
75,096 $2.99 Million
Q3 2017

Nov 13, 2017
BUY
$36.75 - $49.65 $2.71 Million - $3.67 Million
73,869
73,869 $2.96 Million

Others Institutions Holding SUPN

# of Institutions
260
Shares Held
59.3M
Call Options Held
47.9K
Put Options Held
13.1K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.82B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Nicholas Investment Partners, LP Portfolio

Follow Nicholas Investment Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Investment Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email